Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has a $4.00 price objective on the stock.

A number of other research firms also recently commented on ATNM. B. Riley downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $16.00 to $2.00 in a research report on Wednesday, August 7th. Maxim Group cut their price objective on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.40.

Actinium Pharmaceuticals Stock Down 9.1 %

Shares of NYSE ATNM opened at $1.50 on Friday. Actinium Pharmaceuticals has a 52-week low of $1.33 and a 52-week high of $10.24. The stock has a market capitalization of $46.80 million, a price-to-earnings ratio of -1.08 and a beta of 0.14. The company has a 50 day moving average price of $1.79.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals during the 2nd quarter valued at approximately $92,000. Bank of New York Mellon Corp raised its holdings in shares of Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Actinium Pharmaceuticals in the second quarter worth $142,000. Finally, Interchange Capital Partners LLC acquired a new stake in shares of Actinium Pharmaceuticals during the third quarter worth $37,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).